p110-beta subunit inhibitor (GSK/Cincinnati Children's Hospital Medical Center/Emory University)

N/A

Report date: 2025/01/26 15:41:09
NME

Base Information

Drug Namep110-beta subunit inhibitor (GSK/Cincinnati Children's Hospital Medical Center/Emory University)
Drug Alias Namep110-beta subunit inhibitor (GlaxoSmithKline/Cincinnati Children's Hospital Medical Center/Emory University)GSK-2702926A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPI3-kinase class I inhibitors
TargetsPI3-kinase class I
Therapy Area/IndicationsFragile X SyndromeNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcCincinnati Children'S Hospital Medical CenterEmory University
Inactive CompaniesN/A
Active IndicationsFragile X SyndromeNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A